Familial Chylomicronemia Syndrome Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Ionis Pharmaceuticals, Akcea Therapeutics, Novar

DelveInsight Business Research LLP

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Highlights 

• Key Companies working on Familial Chylomicronemia Syndrome  Disease include Ionis Pharmaceuticals, Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V. and many others.

• Key Therapies included in the Familial Chylomicronemia Syndrome  Disease market include WAYLIVRA (volanesorsen), Olezarsen, ARO-APOC3, and many others 

Familial Chylomicronemia Syndrome Disease Overview

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder estimated to affect 1-2 individuals per million. It is a serious disease that prevents the body from breaking down fats consumed through the diet, or triglycerides. These triglycerides are carried in the blood by large structures called chylomicrons.

Familial Chylomicronemia Syndrome  Disease Epidemiology Insights

• Familial hyperchylomicronemia syndrome is a rare and under-reported condition due to its vague symptoms. Therefore, one can only estimate and cannot state its true prevalence with high confidence. It is estimated to affect 3000 to 5,000 patients globally and is present in 1 to 10 individuals per every one million population.

Click here to learn more about the Familial Chylomicronemia Syndrome  Disease Market Landscape

The Report Covers the Familial Chylomicronemia Syndrome  Disease Epidemiology Segmented by:

• Familial Chylomicronemia Syndrome Disease prevalent cases 

• Familial Chylomicronemia Syndrome Disease incident cases 

• Familial Chylomicronemia Syndrome Disease treatment cases 

• Familial Chylomicronemia Syndrome Disease diagnosed cases 

Familial Chylomicronemia Syndrome Disease Market Outlook 

The available Familial Chylomicronemia Syndrome treatment choices can be separated into managing acute crises related to pancreatitis and chronic management of hypertriglyceridemia to reduce the risk of future episodes. Current pharmacological treatment options for patients suffering from Familial Chylomicronemia are fibrates, niacin, omega-3, and statins. However, in severely interfered cases, these are often ineffective in lowering TG levels. There is a lack of approved therapies for the Familial Chylomicronemia Syndrome market. The United States FDA approves no drug for managing Familial Chylomicronemia Syndrome; likewise, no therapy is approved in Japan. However, the EMA granted marketing authorization to WAYLIVRA (Volanesorsen) in the EU in May 2019. The drug has also been granted ODD by the US FDA and EMA but failed to get approval in the US.

Key Companies Working in the Familial Chylomicronemia Syndrome  Disease Market

• Ionis Pharmaceuticals Inc.

• Akcea Therapeutics

• Novartis Pharmaceuticals

• Arrowhead Pharmaceuticals

• UniQure Biopharma B.V.

And many others 

Familial Chylomicronemia Syndrome  Disease Therapies Covered and Analyzed in the Report

• WAYLIVRA (volanesorsen)

• Olezarsen

• ARO-APOC3

And many others

Learn more about the Key Companies and Emerging Therapies in the Familial Chylomicronemia Syndrome  Disease Market

Table of Contents 

1.  Key Insights 

2.  Familial Chylomicronemia Syndrome  Disease Introduction 

3.  Executive Summary of Familial Chylomicronemia Syndrome Disease            

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Familial Chylomicronemia Syndrome Disease  Emerging Therapies

7.  Familial Chylomicronemia Syndrome  Disease  Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Familial Chylomicronemia Syndrome  Disease Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services